Ignite International Brands, Ltd. (the “Company”), a global super-premium cannabis and CBD investment company, today is pleased to announce that, further to its February 26, 2019 news release, it has signed definitive agreements for the manufacture and distribution of CBD products in the United Kingdom with Taylor Mammon & Nathan Limited (“Taylor Mammon”). This agreement also includes the option for the Company to expand into other strategic European markets. Taylor Mammon is a leading cannabidiol (CBD) manufacturer and distributor of white label CBD solutions, based in the United Kingdom.

Under the agreements, Taylor Mammon will, under exclusive Ignite license in the United Kingdom, manufacture, package and distribute a wide array of premium Ignite branded CBD products to select wholesale and retail channels. The Company and Taylor Mammon are jointly developing a comprehensive marketing program that will support the launch of Ignite branded products. The Company will also draw on its marketing expertise and the brand recognition of the Ignite trademark, the iconic goat’s skull logo and founder Dan Bilzerian who has amassed a global social media fan base of over 42 million followers across the leading social media platforms.


Taylor Mammon will also serve as Ignite’s fulfilment partner on its launch of its rest-of-world ecommerce platform scheduled for Q3 2019.

The Company intends to build upon this strategic distribution relationship to introduce a host of Ignite branded products to legal European CBD and cannabis markets.

“We look forward to the power of this partnership to drive CBD market leadership in this emerging UK hyper-growth category,” said Eddie Mattei, Chief Financial Officer of Ignite International Brands, Ltd.  “We’ve seen what the power of Dan’s social media super-influencer status and product expertise has done for Ignite in North America, and we look forward to building on this success in the UK with an established leader such as Taylor Mammon.”

Added Taylor Mammon CEO David Taylor, “It is an honour to be working with the highly professional team at Ignite, they are without a doubt a spectacular company that is about to create a giant footprint into the global CBD markets, and we are proud to be working with them in what I know will be a remarkable relationship”.

About Ignite International Brands, Ltd.

Ignite International Brands, Ltd. is an investment company with a focus on opportunities in the Canadian and global cannabis and CBD sector. The Company has a Trademark & Copyright License Agreement with Ignite International, Ltd., a company founded by Dan Bilzerian, that permits it to market, promote, manufacture, sell, and distribute Ignite branded cannabis and CBD products in Canada and in all international markets other than the United States, as well as investments in CBD cannabis and cannabis-related companies.

About Taylor Mammon Ltd.

Taylor Mammon Ltd. (www.taylormammon.com) is a privately held, established specialist white label manufacturer.  Taylor Mammon sees the benefits in the power of CBD and have created a Company to allow people to have total ownership over their brands and benefit from all of the exciting applications of CBD. Taylor Mammon innovates and creates new products to meet our partners’ rigorous demands.

THE CANADIAN SECURITIES EXCHANGE (CSE) HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING AND OTHER INFORMATION: This news release includes certain “forward-looking statements” under applicable Canadian securities legislation. Forward-looking statements include, but are not limited to, statements with respect to: the execution of the business plans of the Company and Ignite International, Ltd., the entry into the European cannabis market, the expansion of the manufacture and distribution agreement into other European markets and the future value of European legal cannabis markets. Forward-looking statements are necessarily based upon several estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors that may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include, but are not limited to: general business, economic, competitive, political and social uncertainties; ability of the parties to give effect to their respective business plans; reliance on Dan Bilzerian and the Ignite brand which may not prove to be as successful as contemplated; the uncertainties surrounding the cannabis industry in North America, Europe and globally; and the ability of the Company to negotiate and execute definitive agreements with the European white label manufacturer. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. In this regard, there can be no assurance that the investment transaction referred to herein will close. Accordingly, readers should not place undue reliance on forward-looking statements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

For further information: please contact: Ryan Troup, Circadian Group, Tel: 1-866-219-8112, Email: info@circadian-group.com

Source: www.newswire.ca

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less